Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Asma Dilawari

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
The Neurologist|March 3, 2011
Intracranial rosai-dorfman: a clinical challengeRabih Said, Francois Abi-Fadel, Jotica Talwar, et al.
International Journal of General Medicine|July 26, 2014
Lung cancer trends: smoking, obesity, and sex assessed in the Staten Island University's lung cancer patientsShilpi Gupta, Samer Hassan, Vijaya R Bhatt, et al.
Clinical Breast Cancer|January 4, 2015
Patterns of 21-gene assay testing and chemotherapy use in black and white breast cancer patientsVanessa B Sheppard, Suzanne C O'Neill, Asma Dilawari, et al.
The Oncologist|January 29, 2021
Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer?Asma Dilawari, Christopher Gallagher, Princess Alintah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2025
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast CancerAsma Dilawari, Hui Zhang, Mirat Shah, et al.
Health and Technology|August 27, 2019
Providers' Perspectives on Adherence to Hormonal Therapy in Breast Cancer Survivors. Is there a Role for the Digital Health Feedback System?Alejandra Hurtado de Mendoza, Mark Cabling, Asma Dilawari, et al.
Cancer Discovery|December 2, 2022
Highlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug DevelopmentElizabeth S Duke, Michael J Fusco, Patrick DeMoss, et al.
Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc|May 9, 2025
Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors in the Adjuvant Setting: An FDA Pooled AnalysisAsma Dilawari, Mori J Krantz, Ilynn Bulatao, et al.
Contemporary Clinical Trials Communications|July 17, 2018
PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancerFilipa Lynce, Mervat Saleh, Ayesha Shajahan-Haq, et al.
Anticancer Research|April 12, 2012
A pilot study of letrozole for one year in women at enhanced risk of developing breast cancer: effects on mammographic densityJulia Smith, Asma Dilawari, Giske Ursin, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
The Neurologist|March 3, 2011
Intracranial rosai-dorfman: a clinical challengeRabih Said, Francois Abi-Fadel, Jotica Talwar, et al.
International Journal of General Medicine|July 26, 2014
Lung cancer trends: smoking, obesity, and sex assessed in the Staten Island University's lung cancer patientsShilpi Gupta, Samer Hassan, Vijaya R Bhatt, et al.
Clinical Breast Cancer|January 4, 2015
Patterns of 21-gene assay testing and chemotherapy use in black and white breast cancer patientsVanessa B Sheppard, Suzanne C O'Neill, Asma Dilawari, et al.
The Oncologist|January 29, 2021
Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer?Asma Dilawari, Christopher Gallagher, Princess Alintah, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2025
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast CancerAsma Dilawari, Hui Zhang, Mirat Shah, et al.
Health and Technology|August 27, 2019
Providers' Perspectives on Adherence to Hormonal Therapy in Breast Cancer Survivors. Is there a Role for the Digital Health Feedback System?Alejandra Hurtado de Mendoza, Mark Cabling, Asma Dilawari, et al.
Cancer Discovery|December 2, 2022
Highlights of FDA Oncology Approvals in 2022: Tissue-Agnostic Indications, Dosage Optimization, and Diversity in Drug DevelopmentElizabeth S Duke, Michael J Fusco, Patrick DeMoss, et al.
Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc|May 9, 2025
Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors in the Adjuvant Setting: An FDA Pooled AnalysisAsma Dilawari, Mori J Krantz, Ilynn Bulatao, et al.
Contemporary Clinical Trials Communications|July 17, 2018
PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancerFilipa Lynce, Mervat Saleh, Ayesha Shajahan-Haq, et al.
Anticancer Research|April 12, 2012
A pilot study of letrozole for one year in women at enhanced risk of developing breast cancer: effects on mammographic densityJulia Smith, Asma Dilawari, Giske Ursin, et al.
Pageof 2